SIM0689 / Simcere - LARVOL DELTA

A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=472 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2027 ➔ Jul 2026

Enrollment open • First-in-human • Trial initiation date • Oncology • Solid Tumor

A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=472 | Not yet recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Oncology • Solid Tumor

Simcere Pharmaceutical Group…is pleased to announce that SIM0689, a bispecific antibody targeting PD-1/VEGF and self-developed by the Group, has received the Clinical Trial Approval issued by the National Medical Products Administration of China, and is intended for commencing the clinical trial for advanced solid tumors (HKEXnews)

New trial • Solid Tumor

SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies (AACR 2026) - "SCR-M015 inhibits PD-1/PD-L1 signaling and VEGF-A/VEGFR2 signaling in vitro and shows potent and superior anti-tumor activity in vivo. These preclinical data demonstrates the promising potential for further clinical investigation in various types of tumors."

Bispecific • Preclinical • Oncology • IFNG • IL2 • PD-1